P584: OVERALL SURVIVAL WITH INTENSIVE CHEMOTHERAPY (IC) VS NON-IC IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AML FROM THE CONNECT® MYELOID DISEASE REGISTRY INELIGIBLE FOR RANDOMIZED CLINICAL TRIALS (RCT). (23rd June 2022) - Erba, H.; Pollyea, D.; Sekeres, M.; Garcia-Manero, G.; Seiter, K.; DeGutis, I.; Kiselev, P.; McBride, A.; Yu, E.; Roboz, G.